This multi-pronged action enhances insulin sensitivity, curbs appetite, and increases energy expenditure, setting it apart from existing mono- or dual-agonists
The Therapeutic Goods Administration's (TGA) warning covers the following glucagon-like peptide-1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and obesity: Semaglutide, sold as Ozempic, Wegovy Tirzepatide, sold as Mounjaro Dulaglutide, sold as Trulicity Liraglutide, sold as Saxenda The TGA said the products had the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION)
Mounjaro currently carries a significant monthly expense
doi:10.3928/01477447-20151222-12 Carender CN, Glass NA, DeMik DE, Elkins JM, Brown TS, Bedard NA
Welcome to the fam, Lemme GLP-1 Daily